Abiraterone and Prostate Cancer: What You Need to Know About This Treatment Combination
"Uncover how combining abiraterone with prednisolone is changing the landscape for metastatic castration-sensitive prostate cancer, offering new hope and improved outcomes."
Prostate cancer remains a significant health concern for men worldwide. As research continues to evolve, new treatment strategies emerge, offering improved outcomes and enhanced quality of life. One such advancement involves the use of abiraterone in combination with prednisolone for treating metastatic castration-sensitive prostate cancer (mCSPC).
Two pivotal phase 3 trials have highlighted the benefits of this combination: the LATITUDE trial and the STAMPEDE trial. These studies have demonstrated that adding abiraterone to conventional androgen deprivation therapy (ADT) can significantly improve overall survival and radiographic progression-free survival (rPFS) in patients with mCSPC.
This article delves into the details of these trials, explaining how abiraterone works, what the studies revealed, and what this means for men diagnosed with prostate cancer. By understanding the latest research, patients and their families can make informed decisions about their treatment options.
Five-Year Outcomes
A February 2024 report of final results for short-course abiraterone acetate found 97% testosterone recovery and 97% biochemical progression-free survival at five years. The authors said these data support comparative evaluation of the approach. The supplied source does not provide further comparative results.
Dose and Practical Barriers
Abiraterone acetate is widely used for metastatic castration-resistant prostate cancer (mCRPC), but the standard dose described in a 2026 report is 1,000 mg while fasting. The report identifies strict fasting requirements and financial toxicity as challenges, particularly in resource-constrained settings. A separate study description says researchers compared low-dose and standard-dose abiraterone, assessing radiographic and prostate-specific antigen progression-free survival.
From Discovery to Recommendation
The Institute of Cancer Research describes its work as validating inhibitors of androgen production as an effective treatment and discovering and developing abiraterone. Cancer Research UK reports that by the mid-1990s, researchers Jarman, Barrie, and colleagues had shown the drug worked in cancer cells and in animals with prostate cancer. In 2023, the Institute of Cancer Research marked over a decade since abiraterone was first recommended by NICE in England for advanced prostate cancer.
Understanding Abiraterone and Its Role in Prostate Cancer Treatment
Abiraterone is an androgen biosynthesis inhibitor, meaning it reduces the production of androgens (male hormones) in the body. Prostate cancer cells rely on androgens to grow and spread, so by lowering androgen levels, abiraterone can slow down or stop the progression of the disease. It is typically prescribed with a low dose of prednisolone (a steroid) to counteract potential side effects.
- LATITUDE Trial: This double-blinded, placebo-controlled trial involved 1199 patients with newly diagnosed mCSPC. Patients were randomized to receive either abiraterone plus prednisolone or a placebo, in addition to ADT. The results showed a significant improvement in overall survival and rPFS for those in the abiraterone group. Specifically, the risk of death was reduced by 38%, and the median rPFS was 33 months in the abiraterone arm compared to 14.8 months in the placebo arm.
- STAMPEDE Trial: This multiarm, multistage trial randomized 1917 patients with metastatic, node-positive, or high-risk locally advanced prostate cancer. Unlike LATITUDE, STAMPEDE did not have a placebo control. The study compared ADT alone to ADT plus abiraterone. The results indicated that adding abiraterone significantly improved overall survival and failure-free survival (FFS). The 3-year overall survival rate was 83% in the abiraterone arm and 76% in the control arm, representing a 37% reduction in the relative risk of death.
AMPLITUDE Trial
The multinational phase 3 AMPLITUDE trial examined adding niraparib to abiraterone plus prednisone. It focused on patients with homologous recombination repair (HRR) alterations. The trial was designed to determine whether the addition of niraparib results in longer radiographic progression-free survival.
Evidence and Long-Term Safety Gaps
A Cochrane review rated the evidence as moderate in certainty for quality of life, cancer-specific survival, time to disease progression, and discontinuation due to adverse events. It noted that study limitations reduced confidence, although estimates were likely to be close to the actual effects. Separately, final results from two randomized phase 3 trials noted that they lacked a detailed assessment of long-term metabolic toxic effects of intensified hormone treatment with androgen deprivation therapy and abiraterone, with or without enzalutamide.
Survival Benefit in Trial Data
A systematic review and meta-analysis reported results from LATITUDE (NCT01715285) and STAMPEDE (NCT00268476), which together represented 82% of the men randomized to abiraterone acetate plus prednisone and androgen deprivation therapy versus androgen deprivation therapy alone. Across those two trials, the combination was associated with a 38% reduction in the risk of death (hazard ratio 0.62; 95% confidence interval 0.53–0.71; p = 0.55 × 10−10). The authors said this translated into a 14% absolute improvement in three-year overall survival.
The Future of Abiraterone in Prostate Cancer Treatment
The success of abiraterone in treating mCSPC has opened new avenues for research and treatment strategies. As ongoing trials like PEACE1 continue to explore the benefits of combining abiraterone with other therapies, the future looks promising for men facing this diagnosis. With a focus on improving patient outcomes and quality of life, the integration of abiraterone into standard treatment protocols marks a significant step forward in the fight against prostate cancer.
Androgen Synthesis Inhibition
The supplied source describes abiraterone acetate as a drug that blocks endogenous androgen synthesis. It states that abiraterone acetate plus prednisone is indicated for metastatic castration-resistant prostate cancer. The source therefore presents androgen synthesis blockade as the mechanism underlying this treatment combination.
Emerging Treatment Landscape
A 2026 ZERO Cancer blog covers prostate cancer treatment updates, including FDA approvals, targeted therapies, and clinical trial results. A 2026 market report says emerging agents—including novel androgen receptor inhibitors, immunotherapies, and targeted radioligand treatments—are challenging abiraterone’s market dominance. Together, these sources describe an evolving treatment landscape, though they do not provide specific clinical outcomes for those approaches.
Pharmacology and Clinical Experience
A review of abiraterone acetate covers the drug’s development and pharmacological characteristics. It also discusses its effects on the androgen–androgen receptor signaling axis. The review includes combined experience from clinical trials.
Real-World Evidence
An ESMO Open report notes that limited real-world data existed on the effectiveness and safety of abiraterone acetate plus prednisone in chemotherapy-naïve patients with mCRPC. The prospective COSMiC study set out to gather real-world data on metastatic castration-resistant prostate cancer in Canada. Separately, a Lancet Oncology commentary describes an early-access protocol trial of abiraterone in patients whose mCRPC had progressed after taxane chemotherapy and possibly one additional regimen.